BSE Live
Apr 21, 16:01Prev. Close
707.35
Open Price
707.40
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 21, 15:55Prev. Close
706.50
Open Price
705.00
Bid Price (Qty.)
698.10 (268)
Offer Price (Qty.)
0.00 (0)
| Profit & Loss account of Astec Lifesciences (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 378.15 | 457.70 | 628.17 | 676.57 | 554.87 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue From Operations [Net] | 378.15 | 457.70 | 628.17 | 676.57 | 554.87 | |
| Total Operating Revenues | 381.30 | 458.18 | 628.17 | 676.57 | 554.87 | |
| Other Income | 5.56 | 5.58 | 13.04 | 10.46 | 7.67 | |
| Total Revenue | 386.86 | 463.76 | 641.20 | 687.03 | 562.54 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 248.86 | 318.82 | 460.83 | 444.82 | 344.60 | |
| Purchase Of Stock-In Trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | 48.08 | 0.46 | -59.59 | -58.00 | -2.55 | |
| Employee Benefit Expenses | 61.10 | 61.74 | 52.26 | 50.31 | 38.35 | |
| Finance Costs | 36.71 | 25.24 | 20.74 | 9.09 | 4.79 | |
| Depreciation And Amortisation Expenses | 43.77 | 36.31 | 33.71 | 34.42 | 25.71 | |
| Other Expenses | 89.46 | 83.06 | 98.40 | 85.36 | 62.97 | |
| Total Expenses | 527.98 | 525.64 | 606.35 | 565.99 | 473.87 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | -141.12 | -61.88 | 34.85 | 121.04 | 88.67 | |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | -141.12 | -61.88 | 34.85 | 121.04 | 88.67 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 0.00 | 0.00 | 0.00 | 28.61 | 23.24 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | -6.31 | -14.89 | 9.33 | 2.61 | -0.61 | |
| Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 1.35 | |
| Total Tax Expenses | -6.31 | -14.89 | 9.33 | 31.22 | 23.98 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | -134.81 | -46.99 | 25.52 | 89.82 | 64.69 | |
| Profit/Loss From Continuing Operations | -134.81 | -46.99 | 25.52 | 89.82 | 64.69 | |
| Profit/Loss For The Period | -134.81 | -46.99 | 25.52 | 89.82 | 64.69 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | -68.74 | -23.96 | 13.02 | 45.85 | 33.05 | |
| Diluted EPS (Rs.) | -68.74 | -23.96 | 13.02 | 45.83 | 33.02 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 0.00 | 2.94 | 2.94 | 2.94 | 2.94 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Equity Dividend Rate (%) | 0.00 | 0.00 | 15.00 | 15.00 | 15.00 |
03.02.2026
Astec Life Consolidated December 2025 Net Sales at Rs 124.72 crore, up 32.88% Y-o-Y
03.02.2026
Astec Life Standalone December 2025 Net Sales at Rs 124.72 crore, up 32.88% Y-o-Y
03.11.2025
Astec Life Standalone September 2025 Net Sales at Rs 73.72 crore, down 25.19% Y-o-Y
30.10.2025
Astec Life Consolidated September 2025 Net Sales at Rs 73.72 crore, down 25.19% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth